Stock Trading

BSD Medical Corporation develops, manufactures, markets, and services medical systems that deliver precision-focused radio frequency (RF) or microwave energy into diseased sites of the body, heating them to specified temperatures as required by a variety of medical therapies. The company develops technology and products for thermal ablation and hyperthermia cancer therapy through various techniques, which include thermal ablation that ablates soft tissues at high temperatures through focused microwave energy; superficial hyperthermia, which non-invasively treats cancerous tumors located within a few centimeters of the surface of the body, such as melanoma and recurrent breast cancer; internal or interstitial hyperthermia that treats tumors in combination with internal radiation therapy by inserting tiny microwave antennae that deliver hyperthermic microwave energy to tumors through the same catheters used to deliver radioactive materials to tumors for radiation therapy; and deep hyperthermia, which non-invasively treats tumors located deep within the body, including various problematic cancer sites located in the pelvis. It offers MicroThermX-100 microwave ablation system for ablation of soft tissue; MicroThermX-180 microwave ablation system that provides minimally invasive access to the target tissue, and could be used in open surgical, as well as in percutaneous ablation procedures; BSD-500 systems to deliver either superficial or interstitial hyperthermia therapy or both; and BSD-2000 family of products that non-invasively deliver localized therapeutic heating to solid tumors by applying RF energy to certain cancerous tumors, as well as BSD-2000/3D and BSD-2000/3D/MR. The company serves clinics, hospitals, and institutes that treat cancer in the United States and internationally. BSD Medical Corporation was founded in 1978 and is based in Salt Lake City, Utah.

Valuation Measures
Market Cap (intraday)5: 131.63M
Enterprise Value (Dec 14, 2010)3: 91.99M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye Aug 31, 2011)1: N/A
PEG Ratio (5 yr expected)1: N/A
Price/Sales (ttm): 51.83
Price/Book (mrq): 8.80
Enterprise Value/Revenue (ttm)3: 51.14
Enterprise Value/EBITDA (ttm)3: -11.76

Financial Highlights
Fiscal Year
Fiscal Year Ends: Aug 31
Most Recent Quarter (mrq): May 31, 2010

Profitability
Profit Margin (ttm): N/A
Operating Margin (ttm): -442.79%

Management Effectiveness
Return on Assets (ttm): -38.56%
Return on Equity (ttm): -66.44%

Income Statement
Revenue (ttm): 1.80M
Revenue Per Share (ttm): 0.08
Qtrly Revenue Growth (yoy): -86.70%
Gross Profit (ttm): 81.27K
EBITDA (ttm): -7.82M
Net Income Avl to Common (ttm): -7.96M
Diluted EPS (ttm): -0.35
Qtrly Earnings Growth (yoy): N/A

Balance Sheet
Total Cash (mrq): 7.48M
Total Cash Per Share (mrq): 0.30
Total Debt (mrq): 0.00
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 13.86
Book Value Per Share (mrq): 0.43

Cash Flow Statement
Operating Cash Flow (ttm): -5.35M
Levered Free Cash Flow (ttm): -3.74M

Stock Price History
Beta: 0.84
52-Week Change3: 100.00%
S&P500 52-Week Change3: 11.34%
52-Week High (Aug 18, 2010)3: 3.58
52-Week Low (Jul 14, 2010)3: 0.86
50-Day Moving Average3: 4.99
200-Day Moving Average3: 2.76

Share Statistics
Avg Vol (3 month)3: 1,273,340
Avg Vol (10 day)3: 928,643
Shares Outstanding5: 24.93M
Float: 16.18M
% Held by Insiders6: 38.10%
% Held by Institutions6: 4.20%
Shares Short (as of Nov 30, 2010)3: 2.81M
Short Ratio (as of Nov 30, 2010)3: 1.70
Short % of Float (as of Nov 30, 2010)3: 20.90%
Shares Short (prior month)3: 2.19M

Dividends & Splits
Forward Annual Dividend Rate4: N/A
Forward Annual Dividend Yield4: N/A
Trailing Annual Dividend Yield3: N/A
Trailing Annual Dividend Yield3: N/A
5 Year Average Dividend Yield4: N/A
Payout Ratio4: N/A
Dividend Date3: N/A
Ex-Dividend Date4: N/A
Last Split Factor (new per old)2: N/A
Last Split Date3: N/A

SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ:BSDM - News) (Company or BSD) today announced success in the Company’s initial product launch for the MicroThermX Microwave Ablation System (MTX-180). BSD’s initial product launch has been focused on placement of a select number of systems with pivotal, high-profile, interventional oncology, key opinion leaders. BSD has successfully placed three of these systems and will shortly place a fourth system.



The first two systems have been placed at clinical sites in Salt Lake City, Utah – St. Mark’s Hospital, part of MountainStar Healthcare, and the George E. Wahlen Department of Veterans Affairs Medical Center. The third system has been placed at William Beaumont Hospital in Detroit, Michigan, and the fourth system is pending placement at Rhode Island Hospital. BSD has received very positive feedback from the clinicians following liver treatments with the MTX-180.



Referring to his first patient treatment, James G. Carlisle, M.D., an interventional oncologist, stated, “BSD has hit the ball out of the park. The MicroThermX Microwave Ablation System provides multiple benefits, including quick set-up time, ease of use, and a big reduction in footprint. Of course, the ablation zones are large and predictable.”



Dr. Carlisle has the most extensive experience in providing image-guided, minimally invasive cancer therapies in the Intermountain West. He treats patients at St. Mark’s Hospital and the George E. Wahlen Department of Veterans Affairs Medical Center.



About St. Mark’s Hospital and MountainStar Healthcare



Established as Utah’s first hospital in 1872, St. Mark’s Hospital brings nearly 140 years of experience to delivering patient care. It is the only one in the state to achieve the HealthGrades Patient Safety Excellence Award in 2010, and to sustain a Distinguished Hospital Award for Clinical Excellence for three consecutive years. St. Mark’s Hospital has been ranked as a 100 Top Hospital® for cardiovascular care eight times, and as an overall 100 Top Hospital five times by Thomson Reuters. www.stmarkshospital.com.



MountainStar Healthcare delivers nationally recognized patient care—when and where it’s needed. It provides high-quality healthcare services and advanced technologies at six hospitals and the only satellite emergency department in Utah, as well as two hospitals in Idaho, one in Alaska, and a growing number of physician, surgery and imaging centers. www.notbiggerjustbetterhealth.com.



About George E. Wahlen Department of Veterans Affairs Medical Center



The George E. Wahlen Department of Veterans Affairs Medical Center (VA), located in Salt Lake City, is the major referral center for the Intermountain West veteran population. The VA provides complete and comprehensive care ranging from basic primary care to complex surgical procedures.



About the MicroThermX Microwave Ablation System



The MTX-180 is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MTX-180 is the first of its kind that allows delivery of higher power levels using a single generator. The MTX-180 utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MTX-180 introduces into the Company’s product line an innovative, high-end disposable that is used in each ablation treatment, and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MTX-180 for ablation of soft tissue. BSD has also received CE Marking for the MTX-180 System.



About BSD Medical Corporation



BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to ablate and destroy soft tissue. The Company has developed extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.



Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

Nice move on todays news + 44% This one has been a very popular play in our chat room for the past several weeks Congrats to all who took advantage of this play!!!!

BSDM has been reported on a newscast here in Detroit, as it turns out Beaumont Hospital has a recipient of a placement of BSD Medicals' MTX-80, one of 4 hospitals nationwide. The reviews were very good. I expect the stock to hover for a time around 3.60-4.25 area until the 2000 is fda approved which can happen any day, and or when the sales team is cut loose after their training, which should end approx. mid to end of April. Here's the link to the quiet little press releases:
http://www.bsdmedical.com/more-press.php. And btw Chuck...appreciate the posting very much, tu.

Press Release Source: BSD Medical Corporation On Wednesday April 20, 2011, 10:00 am

SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ:BSDM - News) (the “Company” or “BSD”) announced today that a U.S. Government medical facility has purchased a BSD-500 Hyperthermia System (BSD-500). “BSD has received purchase orders for eight hyperthermia systems since September 1, 2010, the beginning of BSD's 2011 fiscal year,” stated Harold Wolcott, BSD's President. “Clinical studies have shown that hyperthermia delivered using the BSD-500 can significantly increase the effectiveness of radiation therapy without a significant increase in toxicity for certain tumors. We are excited that this technology will be more widely available to patients throughout the world.”



The BSD-500 Hyperthermia System is used to deliver therapeutic heating (hyperthermia) using either non-invasive (external) hyperthermia, which is delivered using antennas placed over the tumor, or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both. The BSD-500 has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), which is the standard FDA approval required to market Class III medical devices in the United States, for the use of hyperthermia alone or in conjunction with radiation therapy for the treatment of certain tumors.

Hey Chuck...Updated O/S for BSDM is 29.6mm, public float is 21.25mm, and short interest is 3,047,721 current as of May 24, 2011.